This virtual presentation is intended for PhD and postdoc students only, who are seeking full-time opportunities for 2021. This presentation will kick-off our virtual Advanced Degree Candidate (ADC) recruiting season, more events to follow!

USE THIS LINK TO RSVP FOR THIS EVENT, DO NOT RSVP IN HANDSHAKE: http://bit.ly/bcghc

Engineered immune cellsare emerging as a revolutionary therapy that may transform outcomes for cancer patients. Two of these therapies based on chimeric antigen receptor T-cell (CAR-T) technology have received FDA approval and helped extremely ill patients where other therapies have failed - up to 90% of advanced relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) patients in clinical studies saw complete remission of their disease. But a truly novel modality like this - where a patient’s own immune cells are extracted, engineered, and reintroduced to attack their cancer - comes with unprecedented scientific, technical, and operational challenges. Here at BCG, we have partnered with leading biopharmaceutical companies to explore novel strategies to discover, develop, and deliver cell therapies to patients with true unmet need. Garner Soltes, Project Leader from our BCG NewJersey office, will lead this virtual session and walk through his specific experience on a BCG client case, where he, alongside a team of BCG consultants, developed a 10-year strategy and plan to help this client explore and succeed in the emerging cell therapy space.

Learn more about BCG PhD/postdoc recruiting (aka ADC) on our website here: https://www.bcg.com/en-us/careers/students/advanced-degrees.aspx